DERM Journey Medical Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1867066 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.0%
TTM net income YoY41.1%
TTM EPS YoY48.6%
Revenue 3-yr CAGR-4.5%
Net income 3-yr CAGR—
Margins
Gross margin65.9%
Operating margin-2.9%
Net margin-7.3%
FCF margin—
EBITDA margin—
Returns
ROE-17.6%
ROA-5.4%
ROIC (approx.)-5.2%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets68.9%
Debt / equity0.79x
Current ratio1.48x
Interest coverage-0.55x
Cash quality & payout
Operating cash flow / net income1.67x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.97M | $18.51M | $15.96M | $16.08M | $17.63M | $15.01M | $13.14M | $13.62M |
| Cost of revenue | $5.88M | $6.14M | $6.22M | $5.44M | $5.75M | $4.94M | $4.79M | $2.24M |
| Gross profit | $13.08M | $12.37M | $9.74M | $10.64M | $11.88M | $10.07M | $8.35M | $11.38M |
| R&D expense | $51,000 | $54,000 | — | $154,000 | $287,000 | $0 | $39,000 | $218,000 |
| SG&A expense | $12.59M | $10.89M | $10.11M | $9.86M | $12.05M | $11.88M | $10.57M | $10.06M |
| Operating income | -$530,000 | $456,000 | -$1.49M | -$443,000 | -$1.53M | -$2.88M | -$3.32M | $2.23M |
| Interest expense | $919,000 | $906,000 | $892,000 | $933,000 | $937,000 | $937,000 | $891,000 | $831,000 |
| Pretax income | -$1.31M | -$297,000 | -$2.23M | -$1.25M | -$2.31M | -$3.74M | -$4.07M | $1.58M |
| Income tax | $0 | $15,000 | — | $0 | $0 | $60,000 | — | — |
| Net income | -$1.31M | -$312,000 | -$2.23M | -$1.25M | -$2.31M | -$3.80M | -$4.07M | $1.52M |
| EPS (basic) | -0.05 | -0.01 | -0.08 | — | -0.09 | -0.16 | -0.18 | — |
| EPS (diluted) | -0.05 | -0.01 | -0.08 | — | -0.09 | -0.16 | -0.18 | — |
| Weighted avg. shares (diluted) | 28.07M | 27.49M | 27.31M | — | 24.96M | 23.29M | 22.61M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22.32M | $25.64M | $27.22M | $24.09M | $24.95M | $20.29M | $21.07M | $20.30M |
| Receivables | $47.39M | $36.25M | $24.99M | $29.78M | $17.98M | $15.64M | $18.02M | $10.23M |
| Inventory | $7.77M | $8.16M | $9.29M | $9.62M | $11.82M | $12.85M | $12.50M | $14.43M |
| Current assets | $79.26M | $72.78M | $64.97M | $66.87M | $56.39M | $51.27M | $53.99M | $48.18M |
| Intangibles | $24.54M | $25.51M | $26.48M | $27.61M | $28.67M | $29.73M | $30.80M | $31.86M |
| Total assets | $103.85M | $98.36M | $91.53M | $94.59M | $85.19M | $81.16M | $84.96M | $80.24M |
| Current liabilities | $53.52M | $45.77M | $37.83M | $37.44M | $39.72M | $40.48M | $40.22M | $35.17M |
| Short-term debt | $7.50M | $5.00M | $2.50M | — | $5.62M | $3.75M | $1.88M | — |
| Long-term debt | $18.08M | $20.47M | $22.87M | $25.28M | $19.53M | $21.36M | $23.11M | $24.88M |
| Total debt | $25.58M | $25.47M | $25.37M | $25.28M | $25.16M | $25.11M | $24.98M | $24.88M |
| Total liabilities | $71.60M | $66.24M | $60.70M | $62.74M | $59.29M | $61.91M | $63.42M | $60.17M |
| Shareholders' equity | $32.25M | $32.11M | $30.83M | $31.85M | $25.90M | $19.25M | $21.54M | $20.07M |
| Net debt | $3.25M | -$171,000 | -$1.85M | $1.19M | $211,000 | $4.82M | $3.91M | $4.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.44M | -$1.73M | $2.91M | -$6.28M | -$2.38M | -$942,000 | -$2.83M | $2.23M |
| Financing cash flow | $117,000 | $158,000 | $220,000 | $5.43M | $7.04M | $165,000 | $3.60M | $10.62M |
| Stock-based compensation | $1.33M | $1.44M | $989,000 | $1.77M | $1.85M | $1.34M | $1.32M | $1.38M |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.